TargED Biopharmaceuticals to Present First Clinical and New Preclinical Data on TGD001 in Two Oral Sessions at the 2025 ASH Annual Meeting

Utrecht, November 3, 2025 -…

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M)

New investors Fidelity Management &…

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

• USD 361 million round…

EPICS Therapeutics Announces First Cohort Dosed with EP102 in First-In-Patient Oncology Trial and Securement of Additional Financing

Gosselies, Belgium - September 22nd,…

Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients

NVD003 is a bone grafting…

Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia

Novadip is developing NVD003, an…

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

US-based Dieter Weinand is the…

AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using LaunchiT technology

Third asset to advance into…

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

The program, licensed exclusively to…

Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb

No refractures were reported during…